WO2008113881A1 - Compuesto inhibidor dual de las enzimas pde7 y/o pde4, composiciones farmaceúticas y sus aplicaciones - Google Patents
Compuesto inhibidor dual de las enzimas pde7 y/o pde4, composiciones farmaceúticas y sus aplicaciones Download PDFInfo
- Publication number
- WO2008113881A1 WO2008113881A1 PCT/ES2008/070051 ES2008070051W WO2008113881A1 WO 2008113881 A1 WO2008113881 A1 WO 2008113881A1 ES 2008070051 W ES2008070051 W ES 2008070051W WO 2008113881 A1 WO2008113881 A1 WO 2008113881A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oxo
- dihydroquinazoline
- methylthio
- thioxo
- tetrahydroquinazoline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Definitions
- the invention is directed to the field of medical chemistry and more specifically to dual inhibitors of the PDE7 and PDE4 enzymes and their potential to be used in the preparation of pharmaceutical compositions for the treatment of inflammatory or autoimmune processes, and is therefore framed in the pharmaceutical sector.
- the phosphodiesterase enzymatic activity consists in the degradation of cyclic nucleotides (cAMP and cGMP) by hydrolytic breakage of the 3'-phosphodiester bond, giving rise to the corresponding inactive form 5'-monophosphate (Conti, M .; Jin, SL, The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol. 1999, 63, 1-38).
- CAMP and cGMP are generated by the action of adenylate cyclase and guanylate cyclase respectively, acting as second messengers in transduction of intracellular signals.
- PDE inhibitors The interest in developing specific PDE inhibitors is based on the anti-inflammatory and immunosuppressive properties shown by agents capable of increasing the Intracellular cAMP levels (Essayan, DM, Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation. Biochem. Pharmacol. 1999, 57, 965-973; Allison, A. C, Immunosuppressive drugs: The first 50 years and a glance forward. Immunopharmacology 2000, 47, 63-83). Therefore, selective inhibitors of cAMP-specific PDEs may be of interest as a therapy for the treatment of different diseases (Lugnier, C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents.
- PDE Cyclic nucleotide phosphodiesterase
- T lymphocytes those expressed in T lymphocytes are mainly 3B, 4A, 4B, 4D and 7A1 (Ekholm, D .; Hemmer, B .; Gao, G .; Vergelli, M .; Martin, R .; Manganiello, V., Differential expression of cyclic nucleotide phosphodiesterase 3 and 4 activities in human T cell clones specific for myelin basic protein. J. Immunol.
- benzo- and benzothienothiadiazine derivatives developed by the inventors of this patent were the first heterocyclic inhibitors described of PDE7 (Mart ⁇ nez, A .; Castro, A .; Gil, C; Miralpeix, M .; Segarra, V .; Doménech, T .; Beleta, J .; Palacios, J .; Ryder, H .; Miró, X .; Bonet, C; Casacuberta, J .; Azor ⁇ n, F .; Pina, B .; Puigdoménech, P.
- Benzyl derivatives of 2,1,3-benzo- and benzothieno [3,2-a] thiadiazine 2,2-dioxides First phosphodiesterase 7 inhibitors J. Med. Chem., 2000, 43, 683-689; Castro, A .; Abasolo, MI; Gil, C; Segarra, V .; Mart ⁇ nez, A. CoMFA of benzyl derivatives of 2,1, 3-benzo and benzothieno [3,2-a] thiadiazine 2,2-dioxides: clues for the design of phosphodiesterase 7 inhibitors. Eur. J. Med. Chem. 2001, 36, 333-338).
- PDE7 inhibitors have allowed the study of the functions of PDE7A in different cells and tissues. However, although the inhibition of PDE7A does not decrease the proliferation of T cells per se, it does considerably increase the effect on the elevation of cAMP levels that PDE4 inhibitors have (Smith, SJ; Cieslinski, LB; Newton, R .; Donnelly, LE; Fenwick, PS; Nicholson, AG; Barnes, PJ; Barnette, MS; Giembycz, MA Discovery of BRL 50481 [3- (N, N-dimethylsulfonamido) -4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8 + T-lymphocytes.
- An object of the present invention is a compound (understood as a family of compounds) with dual inhibitory activity of the PDE7 and / or PDE4 enzymes, hereinafter composed of the present invention, which presents the formula (I):
- A is an optionally substituted 5, 6 or 7 membered saturated or unsaturated carbocycle or heterocycle, it may be a double bond;
- R 1 R 1 and R 2 are independently selected from the group consisting of hydrogen, halogen, alkyl, haloalkyl, aryl, cycloalkyl, (Z) n -aryl, heteroaryl, -OR 3 ; -C (O) OR 3 , - (Z) n -C (O) OR 3 or -S (O) 1 -, or a pharmaceutically acceptable salt, derivative, prodrugs, solvate or stereoisomers thereof.
- composition of the invention which comprises a compound, in a therapeutically effective amount, of formula (I), or mixtures thereof. same, a pharmaceutically acceptable salt, derivative, prodrug, solvate or stereoisomer thereof together with a pharmaceutically acceptable carrier, adjuvant or vehicle, for administration to a patient.
- Another additional object of the present invention constitutes the use of a compound of the invention of formula (I), or its mixtures for the preparation of a medicament, hereinafter use of a compound of the invention, directed to the treatment of pathologies or diseases inflammatory and / or autoimmune, including, but not limited to, inflammatory bowel disease, inflammatory joint pathologies, atopic dermatitis and other inflammatory dermatological pathologies, neuritis, encephalitis, encephalomyelitis and inflammatory pathologies that affect the central nervous system (multiple sclerosis) or peripheral, myositis, vasculitis, systemic lupus erythematosus, infectious diseases that occur with inflammation, host rejection reactions against grafting, conjunctivitis and inflammatory oculopathies, otitis and mucositis.
- pathologies or diseases inflammatory and / or autoimmune including, but not limited to, inflammatory bowel disease, inflammatory joint pathologies, atopic dermatitis and other inflammatory dermatolog
- the present invention is based on the fact that the inventors have shown that the compounds of formula (I) are dual inhibitors of the PDE7 and / or PDE4 enzymes, more specifically, of the PDE7A1 and / or PDE4D2 enzymes (Example 5), whereby They can be used in the elaboration of pharmaceutical compositions for the treatment of inflammatory or autoimmune processes.
- an object of the present invention is a compound (understood as a family of compounds) with dual inhibitory activity of the PDE7 and / or PDE4 enzymes, hereinafter composed of the present invention, which presents the formula (I):
- A is an optionally substituted 5, 6 or 7 membered saturated or unsaturated carbocycle or heterocycle, - it may be a double bond;
- R, R 1 and R 2 are independently selected from the group consisting of hydrogen, halogen, alkyl, haloalkyl, aryl, cycloalkyl, (Z) n -aryl, heteroaryl, -OR 3 ; -C (O) OR 3 , - (Z) n -C (O) OR 3 or -S (O) 1 -, or a pharmaceutically acceptable salt, derivative, prodrugs, solvate or stereoisomers thereof.
- a particular object of the invention constitutes a compound of the invention of formula 4-oxo-2-thioxo- 1 l 2 l 3 l 4-tetrahydroquinazoline (Compound Ia 1 Figure 1), and more preferably, belonging, by way of illustration and without limiting the scope of the invention, to the following group: 6-Bromo-3-phenyl-4-oxo-2-thioxo-1, 2,3,4-tetrahydroquinazoline (TC.2.30),
- Another particular object of the invention constitutes a compound of
- Another particular object of the invention constitutes a compound of the invention of formula 2,4-dithioxo-1, 2,3,4-tetrahydroquinazoline (Compound Ic, Figure 3), and more preferably, belonging, by way of illustration and without limit the scope of the invention to the following group:
- Another particular object of the invention constitutes a compound of the invention of the formula 2-methylthio-4-thioxo-3,4-dihydroquinazoline (Compound Id, Figure 4), and more preferably, belonging, by way of illustration and without limiting the scope of the invention, to the following group:
- the compounds of the present invention represented by the formula (I), and more specifically, the compounds of formula Ia, Ib, Ic and Id, and the specific compounds belonging to these subfamilies described above may include isomers, depending on the presence of bonds multiple (for example, Z, E), including optical isomers or enantiomers, depending on the presence of chiral centers.
- the individual isomers, enantiomers or diastereoisomers and mixtures thereof fall within the scope of the present invention.
- the term "derivative" includes both pharmaceutically acceptable compounds, that is, derivatives of the compound of formula (I) that can be used in the manufacture of a medicament, as pharmaceutically unacceptable derivatives since these can be useful in the preparation of pharmaceutically acceptable derivatives.
- the nature of the pharmaceutically acceptable derivative is not critical as long as it is pharmaceutically acceptable.
- prodrugs of the compounds of formula (I) include any compound derived from a compound of formula (I), for example, esters, including carboxylic acid esters, amino acid esters, phosphate esters, metal salt sulphonate esters, etc., carbamates, amides, etc., which, when administered to an individual, is capable of providing, directly or indirectly, said compound of formula (I) in said individual.
- said derivative is a compound that increases the bioavailability of the compound of formula (I) when administered to an individual or that enhances the release of the compound of formula (I) in a biological compartment.
- solvate includes both pharmaceutically acceptable solvates, that is, solvates of the compound of formula (I) that can be used in the manufacture of a medicament, as pharmaceutically acceptable solvates, which They can be useful in the preparation of solvates or pharmaceutically acceptable salts.
- the nature of the pharmaceutically acceptable solvate is not critical as long as it is pharmaceutically acceptable.
- the solvate is a hydrate. Solvates can be obtained by conventional solvation methods well known to those skilled in the art.
- the compounds of formula (I), their isomers, salts, prodrugs or solvates will preferably be found in a pharmaceutically acceptable or substantially pure form, that is, having a pharmaceutically acceptable level of purity excluding normal pharmaceutical additives such as diluents and carriers, and not including material considered toxic at normal dosage levels.
- the purity levels for the active ingredient are preferably greater than 50%, more preferably greater than 70%, more preferably greater than 90%. In a preferred embodiment, they are greater than 95% of the compound of formula (I), or of its salts, solvates or prodrugs.
- the compounds of the invention also include compounds that differ only in the presence of one or more isotopically enriched atoms.
- compounds having said structure except for the replacement of a hydrogen with a deuterium or tritium, or the replacement of a carbon with a carbon enriched in 13 C or 14 C or a nitrogen enriched in 15 N, are within of the scope of this invention.
- the compounds described in the present invention, their pharmaceutically acceptable salts, prodrugs and / or solvates as well as the pharmaceutical compositions containing them can be used together with other additional drugs to provide a combination therapy.
- Said additional drugs may be part of the same pharmaceutical composition or, alternatively, may be provided in the form of a separate composition for simultaneous or not simultaneous administration of the pharmaceutical composition comprising a compound of formula (I), or a prodrug, solvate, derivative or a pharmaceutically acceptable salt thereof.
- the compounds of the present invention of formula (I) can be obtained or produced by a chemical synthetic route or obtained from a natural material of different origin.
- a synthetic route of the compounds of the invention of formula (I) and their families is described (see Figure 1 to 4, and Examples 1 to 4), which can be carried out with the data described in Ia present invention by a technician skilled in the art.
- the synthesis process of the compounds of the invention Ia, Ib, Ic and Id, as described in the invention, constitutes another object of the present invention.
- composition of the invention which comprises a compound, in a therapeutically effective amount, of formula (I), or mixtures thereof. same, a pharmaceutically acceptable salt, derivative, prodrug, solvate or stereoisomer thereof together with a pharmaceutically acceptable carrier, adjuvant or vehicle, for administration to a patient.
- Another particular object of the invention constitutes the pharmaceutical composition of the invention in which the compound of formula (I) belongs to one, or several, of the following families of compounds:
- compositions are the adjuvants and vehicles known to those skilled in the art and commonly used in the elaboration of therapeutic compositions.
- therapeutically effective amount refers to the amount of the agent or compound capable of developing inhibition of PDE7 and PDE4 enzymes, calculated to produce the desired effect and, in general, will be determined, between other causes, due to the characteristics of the compounds, including the age, condition of the patient, the severity of the alteration or disorder, and the route and frequency of administration.
- said therapeutic composition is prepared in the form of a solid form or aqueous suspension, in a pharmaceutically acceptable diluent.
- the therapeutic composition provided by this invention can be administered by any appropriate route of administration, for which said composition will be formulated in the pharmaceutical form appropriate to the route of administration chosen.
- the administration of the therapeutic composition provided by this invention is carried out orally, topically, rectally or parenterally (including subcutaneously, intraperitoneally, intradermally, intramuscularly, intravenously, etc.).
- Another additional object of the present invention constitutes the use of a compound of the invention of formula (I), or its mixtures for the preparation of a medicament, hereinafter use of a compound of the invention, directed to the treatment of pathologies or diseases inflammatory and / or autoimmune, including, but not limited to, inflammatory bowel disease, inflammatory joint pathologies, atopic dermatitis and other inflammatory dermatological pathologies, neuritis, encephalitis, encephalomyelitis and inflammatory pathologies that affect the central nervous system (multiple sclerosis) or peripheral, myositis, vasculitis, systemic lupus erythematosus, infectious diseases that occur with inflammation, host rejection reactions against grafting, conjunctivitis and inflammatory oculopathies, otitis and mucositis.
- pathologies or diseases inflammatory and / or autoimmune including, but not limited to, inflammatory bowel disease, inflammatory joint pathologies, atopic dermatitis and other inflammatory dermatolog
- Figure 3. Synthesis scheme of the compounds of formula Ic of the invention.
- Figure 4. Synthesis scheme of the compounds of formula Id of the invention.
- Figure 5. Measurement of the increase in intracellular cAMP of derivatives TC 3.6 and TC 3.14.
- Example 1 General procedure for obtaining 4-oxo-2-thioxo-1,2,3,4-tetrahydroquinazoline derivatives (Compounds Ia, Figure 1)
- Reagents 3-methyl-2-aminobenzoic acid (700 mg, 4.63 mmol), 2,3,4-trifluorophenylisothiocyanate (0.61 ml_, 4.63 mmol), ethanol (46.30 ml_). Reaction time: 4 days. Purification: column chromatography using hexane / ethyl acetate (3: 1) as eluent. Yield: white solid (505.40 mg, 34%).
- Example 2 General procedure for obtaining 2-methylthio-4-oxo-3,4-dihydroquinazoline derivatives (Compounds Ib, Figure 2).
- Reagents TC.2.30 (60 mg, 0.18 mmol), K 2 CO 3 (24.90 mg, 0.18 mmol), DMF (3.91 ml_), methyl iodide (16.81 ⁇ l_, 0, 27 mmol). Reaction time: 3 hours.
- Purification column chromatography using as eluent hexa no / ethyl acetate (4: 1). Yield: white solid (60.80 mg, 97%).
- 6-Bromo-3- (2,3,4-trifluorophenyl) -2-methylthio-4-oxo-3,4-dihydroquinazoline (TC.3.32): It is obtained according to the general methodology described above.
- Reagents TC.3.30 (100 mg, 0.25 mmol), K 2 CO 3 (35.71 mg, 0.25 mmol), DMF (5.60 ml_), methyl iodide (24.10 ⁇ l_, 0, 38 mmol). Reaction time: 4 hours.
- Purification column chromatography using hexane / ethyl acetate as eluent (10: 1). Yield: white solid (66.30 mg, 64%).
- Reagents TC.3.16 (100 mg, 0.32 mmol), K 2 CO 3 (45.46 mg, 0.32 mmol), DMF (7.13 ml_), methyl iodide (30.64 ⁇ l_, 0, 49 mmol). Reaction time: 4 hours. Purification: column chromatography using hexane / ethyl acetate as eluent (5: 1). Yield: white solid (59.50 mg, 57%).
- the catalytic domain of PDE7A1 (aa. 130-482) and the complete enzyme of PDE4D2 (aa. 1-507) were subcloned into pET vectors, overexpressed in E.coli strain BL21, and purified to homogeneity as described in Ia bibliography (Wang, H., Liu, Y., Chen, Y.,
- IC50 is defined as the concentration of compound that inhibits 50% enzymatic activity. All experiments were done in duplicate.
- cellular toxicity measurements of the compounds of formula (I) of the invention were made.
- Cellular toxicity tests have been carried out in a clone of Th2 lymphocytes (D10.G4.1) by flow cytometry and using Propidium Iodide to determine cell death. This technique is based on the quantification of cells in which Propidium Iodide can penetrate because its membrane is damaged, while whole or intact cells do not allow the passage of this fluorochrome that is interspersed in nucleic acids.
- the concentration of cells used was 1x10 6 cells / ml, in a final volume of 200 ⁇ l, in the presence of different concentrations of the inhibitors for 48h. After this time the cells were washed and incubated with 5 ⁇ g / ml of Propidium Iodide for 1 min. The samples thus treated were analyzed by cytometry using a BD FACSCanto TM device. These experiments have been performed in parallel with two commercial inhibitors: Rolipram (PDE4 inhibitor) and BRL 50481 (PDE7 inhibitor). From the analysis of the newly synthesized compounds it can be deduced that those with a more moderate toxicity are: TC3.6, TC3.14 and TC3.15.
- the inhibition of PDEs has the direct effect of increasing cAMP, since its degradation is impeded.
- two compounds of formula (I) of the invention were chosen, specifically: TC 3.6 and TC 3.14 and the concentration of cAMP was measured by means of the Biotrak Enzymeimmunoassay System cAMP kit of Amersham Biosciences .
- the amount of intracellular cAMP increased statistically significantly with PDE7 inhibitors in relation with the control, although a greater increase is observed with the combination of Rolipram with the PDE7 inhibitors, taking place a synergistic effect that considerably increased the intracellular cAMP levels detected by PDE4 inhibition.
- the determination of intracellular cAMP levels in T lymphocytes treated with these inhibitors has shown that the inhibition of PDE7 does not produce high levels of cAMP, but is capable of synergizing the effect produced by the inhibition of PDE4.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200880013379A CN101679314A (zh) | 2007-03-22 | 2008-03-14 | 酶pde7和/或pde4的双重抑制化合物、药物组合物及其用途 |
US12/532,104 US20100152213A1 (en) | 2007-03-22 | 2008-03-14 | Compound that is a dual inhibitor of enzymes pde7 and/or pde4, pharmaceutical compositions and uses thereof |
EP08736738A EP2130823A4 (en) | 2007-03-22 | 2008-03-14 | CONNECTION AS TWO-WAY FIXTURES OF ENZYME PDE7 AND / OR PDE4, PHARMACEUTICAL COMPOSITIONS AND THEIR USE |
AU2008228203A AU2008228203A1 (en) | 2007-03-22 | 2008-03-14 | Compound that is a dual inhibitor of enzymes PDE7 and/or PDE4, pharmaceutical compositions and uses thereof |
CA002682259A CA2682259A1 (en) | 2007-03-22 | 2008-03-14 | Compound that is a dual inhibitor of enzymes pde7 and/or pde4, pharmaceutical compositions and uses thereof |
JP2010500305A JP2010522226A (ja) | 2007-03-22 | 2008-03-14 | 酵素pde7及び/又はpde4の二重阻害化合物、薬剤組成物および利用法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP200700762 | 2007-03-22 | ||
ES200700762A ES2308916B1 (es) | 2007-03-22 | 2007-03-22 | Compuesto inhibidor dual de las enzimas pde7 y/o pde4, composiciones farmaceuticas y sus aplicaciones. |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008113881A1 true WO2008113881A1 (es) | 2008-09-25 |
WO2008113881B1 WO2008113881B1 (es) | 2008-11-06 |
Family
ID=39765419
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2008/070051 WO2008113881A1 (es) | 2007-03-22 | 2008-03-14 | Compuesto inhibidor dual de las enzimas pde7 y/o pde4, composiciones farmaceúticas y sus aplicaciones |
Country Status (8)
Country | Link |
---|---|
US (1) | US20100152213A1 (es) |
EP (1) | EP2130823A4 (es) |
JP (1) | JP2010522226A (es) |
CN (1) | CN101679314A (es) |
AU (1) | AU2008228203A1 (es) |
CA (1) | CA2682259A1 (es) |
ES (1) | ES2308916B1 (es) |
WO (1) | WO2008113881A1 (es) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010133742A1 (es) | 2009-05-20 | 2010-11-25 | Consejo Superior De Investigaciones Científicas (Csic) | Uso de derivados de quinazolinas en enfermedades neurodegenerativas |
WO2012064667A2 (en) | 2010-11-08 | 2012-05-18 | Omeros Corporation | Treatment of addiction and impulse-control disorders using pde7 inhibitors |
US8637528B2 (en) | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
US9220715B2 (en) | 2010-11-08 | 2015-12-29 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
US9796687B2 (en) | 2015-05-22 | 2017-10-24 | Consejo Superior De Investigaciones Cientificas | S-substituted quinazolines and their therapeutic applications for the treatment of diseases mediated by PDE7 |
WO2024038089A1 (en) | 2022-08-18 | 2024-02-22 | Mitodicure Gmbh | Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2118074E (pt) | 2007-02-01 | 2014-03-20 | Resverlogix Corp | Compostos para a prevenção e tratamento de doenças cardiovasculares |
EP2408454A2 (en) | 2009-03-18 | 2012-01-25 | Resverlogix Corp. | Novel anti-inflammatory agents |
CN107530356A (zh) | 2015-03-13 | 2018-01-02 | 雷斯韦洛吉克斯公司 | 用于治疗补体相关疾病之组合物及治疗方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD210452A1 (de) * | 1981-11-16 | 1984-06-13 | Adw Ddr | Verfahren zur herstellung von2,3-diamino-3,4-dihydrochinazolin-4-onen |
ES2038218T3 (es) * | 1987-01-30 | 1993-07-16 | Nisshin Flour Milling Co., Ltd. | Un procedimiento para preparar nuevos derivados de 2-alquilsulfinil-4(3h)-quinazolinona. |
WO2002085906A2 (en) | 2001-04-25 | 2002-10-31 | Altana Pharma Ag | Phthalazinones derivatives useful as pde4/7 inhibitors |
WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
US20060116516A1 (en) * | 2001-06-19 | 2006-06-01 | Pitts William J | Quinazoline and pyrido[2,3-d]pyrimidine inhibitors of phosphodiesterase (PDE) 7 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1059271A (en) * | 1912-05-04 | 1913-04-15 | Davis Bournonville Co | Pantograph apparatus. |
JPS515394B2 (es) * | 1971-10-07 | 1976-02-19 | ||
DE2652144A1 (de) * | 1976-11-16 | 1978-05-18 | Merck Patent Gmbh | Neue chinazolindione |
JPH10259176A (ja) * | 1997-03-17 | 1998-09-29 | Japan Tobacco Inc | 血管新生阻害作用を有する新規アミド誘導体及びその用途 |
DE10230381A1 (de) * | 2002-07-05 | 2004-01-22 | Institut für Medizintechnologie Magdeburg GmbH, IMTM | Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen |
WO2005051974A2 (en) * | 2003-06-09 | 2005-06-09 | The Regents Of The University Of California | Novel molecules for regulating cell death |
-
2007
- 2007-03-22 ES ES200700762A patent/ES2308916B1/es not_active Expired - Fee Related
-
2008
- 2008-03-14 CA CA002682259A patent/CA2682259A1/en not_active Abandoned
- 2008-03-14 JP JP2010500305A patent/JP2010522226A/ja active Pending
- 2008-03-14 WO PCT/ES2008/070051 patent/WO2008113881A1/es active Application Filing
- 2008-03-14 US US12/532,104 patent/US20100152213A1/en not_active Abandoned
- 2008-03-14 AU AU2008228203A patent/AU2008228203A1/en not_active Abandoned
- 2008-03-14 EP EP08736738A patent/EP2130823A4/en not_active Withdrawn
- 2008-03-14 CN CN200880013379A patent/CN101679314A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD210452A1 (de) * | 1981-11-16 | 1984-06-13 | Adw Ddr | Verfahren zur herstellung von2,3-diamino-3,4-dihydrochinazolin-4-onen |
ES2038218T3 (es) * | 1987-01-30 | 1993-07-16 | Nisshin Flour Milling Co., Ltd. | Un procedimiento para preparar nuevos derivados de 2-alquilsulfinil-4(3h)-quinazolinona. |
WO2002085906A2 (en) | 2001-04-25 | 2002-10-31 | Altana Pharma Ag | Phthalazinones derivatives useful as pde4/7 inhibitors |
WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
US20060116516A1 (en) * | 2001-06-19 | 2006-06-01 | Pitts William J | Quinazoline and pyrido[2,3-d]pyrimidine inhibitors of phosphodiesterase (PDE) 7 |
Non-Patent Citations (33)
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8637528B2 (en) | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
US9119822B2 (en) | 2007-03-27 | 2015-09-01 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
US9192610B2 (en) | 2009-05-20 | 2015-11-24 | Consejo Superior De Investigaciones Cientificas | Use of quinazoline derivatives for neurodegenerative diseases |
JP2012527434A (ja) * | 2009-05-20 | 2012-11-08 | コンセホ スペリオール デ インベスティガシオネス シエンティフィカス(セエセイセ) | 神経変性疾患に対するキナゾリン誘導体の使用 |
ES2353093A1 (es) * | 2009-05-20 | 2011-02-25 | Consejo Superior De Investigaciones Cientificas (Csic) | Uso de derivados de quinazolinas y sus composiciones farmacéuticas en enfermedades neurodegenerativas. |
WO2010133742A1 (es) | 2009-05-20 | 2010-11-25 | Consejo Superior De Investigaciones Científicas (Csic) | Uso de derivados de quinazolinas en enfermedades neurodegenerativas |
WO2012064667A2 (en) | 2010-11-08 | 2012-05-18 | Omeros Corporation | Treatment of addiction and impulse-control disorders using pde7 inhibitors |
US9220715B2 (en) | 2010-11-08 | 2015-12-29 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
US11207275B2 (en) | 2010-11-08 | 2021-12-28 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
US11464785B2 (en) | 2010-11-08 | 2022-10-11 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
EP4275752A2 (en) | 2010-11-08 | 2023-11-15 | Omeros Corporation | Treatment of addiction and impulse-control disorders using pde7 inhibitors |
US9796687B2 (en) | 2015-05-22 | 2017-10-24 | Consejo Superior De Investigaciones Cientificas | S-substituted quinazolines and their therapeutic applications for the treatment of diseases mediated by PDE7 |
WO2024038089A1 (en) | 2022-08-18 | 2024-02-22 | Mitodicure Gmbh | Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance |
Also Published As
Publication number | Publication date |
---|---|
CN101679314A (zh) | 2010-03-24 |
ES2308916B1 (es) | 2009-10-29 |
AU2008228203A1 (en) | 2008-09-25 |
ES2308916A1 (es) | 2008-12-01 |
US20100152213A1 (en) | 2010-06-17 |
WO2008113881B1 (es) | 2008-11-06 |
CA2682259A1 (en) | 2008-09-25 |
EP2130823A1 (en) | 2009-12-09 |
JP2010522226A (ja) | 2010-07-01 |
EP2130823A4 (en) | 2011-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2308916B1 (es) | Compuesto inhibidor dual de las enzimas pde7 y/o pde4, composiciones farmaceuticas y sus aplicaciones. | |
ES2809974T3 (es) | Compuestos de indol carboxamida útiles como inhibidores de cinasas | |
AU2009206368B2 (en) | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors | |
ES2394971T3 (es) | Derivados de quinolinas y 6-1H-imidazo-quinazolina, agentes antiinflamatorios y analgésicos potentes nuevos | |
ES2392553T3 (es) | Derivados (3-aril-piperazina-1-ilo) de 6,7-dialcoxiquinazolina, 6,7-dialcoxiftalazina y 6,7-dialcoxiisoquinolina | |
EP2984088B1 (en) | Quinazolines and azaquinazolines as dual inhibitors of ras/raf/mek/erk and pi3k/akt/pten/mtor pathways | |
US20080255110A1 (en) | Imidazoquinoline derivatives as adenosine a3 receptor ligands | |
AU2016228634B2 (en) | Substituted pyrimidine compounds as phosphatidylinositol 3-kinase delta inhibitor and use thereof | |
WO2005080392A1 (ja) | ピラゾロキノロン誘導体およびその用途 | |
WO2014135414A1 (en) | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | |
WO2019154395A1 (zh) | 四氢异喹啉类化合物、其制备方法、包含此类化合物的药物组合物及其用途 | |
ES2393216T3 (es) | [d]Piracin-7-onas condensadas | |
AU2010315361B2 (en) | Quinazoline compounds | |
Haj Mohammad Ebrahim Tehrani et al. | Synthesis and Antimycobacterial Activity of Novel Thiadiazolylhydrazones of 1‐Substituted Indole‐3‐carboxaldehydes | |
WO2006033422A1 (ja) | キノリジノン化合物、およびそのhivインテグラーゼ阻害剤としての利用 | |
ES2328626T3 (es) | Derivados de imidazopiridina utiles como inhibidores de inos. | |
JP2018087173A (ja) | 悪性脳腫瘍治療薬 | |
ES2942442T3 (es) | Derivados de [1,2,4]triazolo[4,3-a]pirazin-8-ona | |
CN114149457B (zh) | 一种苯并[c][1,2]氧杂硼戊环-1(3H)-醇类合物及其用途 | |
EP2057148A1 (en) | Amidine derivatives of 2-heteroaryl-quinazolines and quinolines; potent analgesics and anti-inflammatory agents | |
Gil et al. | Compound that is a dual inhibitor of enzymes PDE7 and/or PDE4, pharmaceutical compositions and uses thereof | |
CN112313222A (zh) | 四氢异喹啉类衍生物、其制备方法及其用途 | |
JP2006519234A (ja) | 新規化合物 | |
CN106565643A (zh) | D‑3‑磷酸甘油酸脱氢酶别构抑制剂及其应用 | |
Deng et al. | Discovery of 5-trifluoromethyl-2-aminopyrimidine derivatives as potent dual inhibitors of FLT3 and CHK1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880013379.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08736738 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2682259 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2010500305 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008736738 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008228203 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12532104 Country of ref document: US |